Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
· Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to..
· Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to..
· Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million
· Reaffirms..
The New York City professional dancer who died from an allergic reaction to incorrectly labeled cookies suffered such extreme..